文献

 

1)

Niwa Y. and Miyashi Y.: Antioxidant action of naturalhealth products and Chinese herbs, Inflammation, 10:79-91,1986.
2) Niwa Y., Miyachi, Y., Ishimoto K. and Kanoh T.: Why are natural plant medicinal products effective in some patients and not in others with the same disease?, Planta Med., 57:299-304,1991.
3) 丹羽靱負：天然の植物・種子のDDS，SOD様作用食品の開発・改良とその薬理・生化学的考察―SOD活性値測定結果の問題点も提起する―，食品工業， 35:42-56,1992.
4) 丹羽靱負，甲斐沼 正，森田罪二，伊丹仁朗，横路謙二郎:遠赤外線焙煎，発酵処理を施した牛黄，食滑石，大黄，茯苓，檳榔樹含有製剤（BG-104）の in viro および再燃 ・転移乳癌への制癌効果，応用薬理，47:465-477,1994.
5） 丹羽靱負， 住 一:焙煎 ･発酵 ･油剤化を施した生薬原料 BG-104 およびアガリクスの bioavailabiliky の増強。―手術不能の肺癌，胃癌，肺 ・肝転移の大腸癌に対する治療効果，日癌治，34:199,1999.
6) Niwa Y.; Clinical and basic research on biological medicine amalgamated with Western medicine. Causes and treatment of atopic dermatitis, malignancy and collagen disease, J. Intl. Soc. Life Info. Sci., 18:172-190,2000.
7) Niwa Y., Kanoh T., Kasama T. and Negishi M.: Activation of antioxidant activity in natural medicinal products by heating, brewing and Iipophilization, Drugs Exptl. Clin. Res., 14:361-372,1988.
8) Niwa Y., Tominaga K. and Yoshida K.: Successful Treatment of severe atopic dermatitis-complicated cataract and male infertility with a natural product, Int. J. Tiss. Reac., 20:63-69,1998.
9) 丹羽靱負 ：活性酸素と皮膚疾患およびSOD製剤による治療，皮膚臨床， 34：89-100,1992.
10) 丹羽靱負，伊丹仁朗，松本浩二朗 ：遠赤外線焙煎 ・発酵 ・油剤化した天然抗酸化剤および制癌剤の自己免疫疾患患者 steroid 漸減補助効果，応用薬理， 54:227-233,1997.
11) 丹羽靱負，河平多宏，松本 健，松本浩二朗 ：遠赤外線放射体のヒト白血球機能，過酸化脂質値，マウス移植癌，ラット薬物肝炎および慢性間接リウマチ患者に及ぼす影響，炎症， 16:425-436,1996.
12) 丹羽靱負 ：遠赤外線放射体の作用機序について―特に天照石 ・天照水のヒト白血球機能，過酸化脂質値，マウス移植癌，ラット薬物肝炎および慢性関節リウマチ患者に及ぼす影響，フレグランスジャーナル， 3:27-34,1999.
13) Niwa Y., Iizawa O., Ishimoto K., Jiang X. and Kanoh T.: Electromagnetic wave emitting products and “Kikoh” potentiate human leukocyte functions, Int. J. Biometeorol., 37:133-138,1993.
14) Jain A.B., Yee L.D., Nalesnik M.A., Youk A., Marsh G., Reyes J., Zak M., Rakela J., Irish W. and Fung J.J.: Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data, Transplantation, 66:1193-1200,1998.
15) Jonas S., Rayes N., Neumann U., Neuhaus R., Bechstein W.O., Guckelberger O., Tullius S.G., Serke S. and Neuhaus P.: De novo malignancies after liver transplantation using tacrolimus-based protocors or cyclosprone-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin, Cancer, 80:1141-1150,1997.
16) Nalesnik M.A., Makowa L. and Starzl T.E.: The diagnosis and treatment of post transplant lymphoproliferative disorders, Curr. Probl. Surg., 25:371-472,1988.
17) Bahram S. and Burneh J.W.; Lymphomatoid papulosis, Arch. Dermatol., 199:189-197,1983.
18) Morikawa T., Wanibuchi H., Morimura K., Ogawa M. and Fukushima S.: Promotion of skin carcinogenesis by dimethylarsinic acid in Keratin (K6)/ODC transgenic mice, Jpn. J. Cancer Res., 91:579-581,2000.
19) Verma A.K., Conrad E.A. and Boutwell R.K.: Induction of mouse epidermal ornithine decarboxylase activity and skin tumors by 7,12-dimethylbenz[α]anthracene: modulation by retinoic acid and 7,8-benzoflavone, Carcinogenesis, 1:607-611,1980.